Genomenon is an artificial intelligence (AI)-driven genomics company based in Ann Arbor, Michigan. Genomenon leverages AI to organize the world’s genomic knowledge and put it at the fingertips of doctors and clinicians to diagnose patients with rare and genetic disease and cancer, and researchers to help create precision medicine targeted at molecular drivers of disease. Beringea U.S. invested in Genomenon in 2022, leading a $20 million Series B round aimed at expanding the company’s commercial operations and the development of its genomic data hub, which services genetic testing labs, hospitals, pharmaceuticals and biopharma companies.
Founded in 2014, Genomenon’s mission was to address the pressing need for faster, more comprehensive variant interpretation of genomic data by combining expert curation with unique machine learning methods designed to keep up with the pace of new publications and present the most relevant information to researchers. Next-generation sequencing (NGS) provides the ability to rapidly and cost effectively sequence patients’ entire genome – creating terabytes of data in the process. The challenge now is making sense of all the data that comes from sequencing. Genomenon was founded to make genomic information actionable to help clinicians rapidly diagnose patients suffering from rare diseases to cancer and to help researchers create precision medicines targeted at the molecular drivers of these diseases.
Clinical diagnoses are rooted in the medical evidence found in peer-reviewed scientific journals. The challenge for clinicians and researchers is finding the scientific evidence that connects genomic variants to diseases to make a diagnosis. It’s extremely difficult and time consuming to scour the internet for scientific papers when authors describe variants in hundreds of different ways – like finding a needle in a haystack. Genomenon’s AI engine indexes and organizes the world’s scientific literature to find every needle in every haystack and put it at the fingertips of clinicians to diagnose patients, and researchers to develop precision medicines.
Genomenon’s Mastermind Genomic Search Engine is used by more than 1,000 genetic testing labs and hospitals worldwide to provide clinical insight into the scientific literature on genomic data. Its Prodigy Genomic Landscapes are used by top Pharma and biopharma companies to gain a profound understanding of the genetic drivers and clinical attributes of any genetic disease, from rare diseases to cancer. These datasets enable Pharma to accelerate target discovery, identify genetic biomarkers for clinical trial stratification, and develop companion diagnostics for regulatory approval.
A comprehensive understanding of genomics is essential to advancing precision medicine, and Genomenon uniquely meets that need in ways that have led to quick adoption in the market. The company makes the Mastermind Genomic Search Engine freely available to a broad range of scientists, academics, and clinicians. Its user base of nearly 20,000 extends to more than 140 countries. In 2020, Genomenon was named Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.